Primary Tumor and Metastasis in Ovarian Cancer Differ in Their Content of Urokinase-type Plasminogen Activator, Its Receptor, and Inhibitors Types 1 and 2

B. Schmalfeldt; W. Kuhn; U. Reuning; L. Pache; M. Sehmitt; F. Jänicke; H. Höfler; P. Dettmar; H. Graeff

Primary Tumor and Metastasis in Ovarian Cancer Differ in Their Content of Urokinase-type Plasminogen Activator, Its Receptor, and Inhibitors Types 1 and 2

B. Schmalfeldt
, W. Kuhn
, U. Reuning
, L. Pache
, M. Sehmitt
, F. Jänicke
, H. Höfler
, P. Dettmar
, H. Graeff

Technical University of Munich

Research output: Contribution to journal › Article › peer-review

103 Scopus citations

Abstract

The relevance of urokinase-type plasminoceli activator (uPA) and plasminogen activator inhibitor (PAI) type I in predicting the survival prob ability of patients with advanced ovarian cancer after radical surgery and adjuvant chemotherapy by assessing the patients' primary tumors has recently been shown by us (W. Kuhn et al., Gynecol. Oncol., 55: 401–409, 1994).

Original language	English
Pages (from-to)	3958-3963
Number of pages	6
Journal	Cancer Research
Volume	55
Issue number	18
State	Published - 15 Sep 1995

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{ebe70a8f9125425180a85f542bc62f39,

title = "Primary Tumor and Metastasis in Ovarian Cancer Differ in Their Content of Urokinase-type Plasminogen Activator, Its Receptor, and Inhibitors Types 1 and 2",

abstract = "The relevance of urokinase-type plasminoceli activator (uPA) and plasminogen activator inhibitor (PAI) type I in predicting the survival prob ability of patients with advanced ovarian cancer after radical surgery and adjuvant chemotherapy by assessing the patients' primary tumors has recently been shown by us (W. Kuhn et al., Gynecol. Oncol., 55: 401–409, 1994).",

author = "B. Schmalfeldt and W. Kuhn and U. Reuning and L. Pache and M. Sehmitt and F. J{\"a}nicke and H. H{\"o}fler and P. Dettmar and H. Graeff",

year = "1995",

month = sep,

day = "15",

language = "English",

volume = "55",

pages = "3958--3963",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "18",

}

TY - JOUR

T1 - Primary Tumor and Metastasis in Ovarian Cancer Differ in Their Content of Urokinase-type Plasminogen Activator, Its Receptor, and Inhibitors Types 1 and 2

AU - Schmalfeldt, B.

AU - Kuhn, W.

AU - Reuning, U.

AU - Pache, L.

AU - Sehmitt, M.

AU - Jänicke, F.

AU - Höfler, H.

AU - Dettmar, P.

AU - Graeff, H.

PY - 1995/9/15

Y1 - 1995/9/15

N2 - The relevance of urokinase-type plasminoceli activator (uPA) and plasminogen activator inhibitor (PAI) type I in predicting the survival prob ability of patients with advanced ovarian cancer after radical surgery and adjuvant chemotherapy by assessing the patients' primary tumors has recently been shown by us (W. Kuhn et al., Gynecol. Oncol., 55: 401–409, 1994).

AB - The relevance of urokinase-type plasminoceli activator (uPA) and plasminogen activator inhibitor (PAI) type I in predicting the survival prob ability of patients with advanced ovarian cancer after radical surgery and adjuvant chemotherapy by assessing the patients' primary tumors has recently been shown by us (W. Kuhn et al., Gynecol. Oncol., 55: 401–409, 1994).

UR - https://www.scopus.com/pages/publications/0029086675

M3 - Article

C2 - 7664262

AN - SCOPUS:0029086675

SN - 0008-5472

VL - 55

SP - 3958

EP - 3963

JO - Cancer Research

JF - Cancer Research

IS - 18

ER -

Primary Tumor and Metastasis in Ovarian Cancer Differ in Their Content of Urokinase-type Plasminogen Activator, Its Receptor, and Inhibitors Types 1 and 2

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this